Thermo Fisher Scientific (TMO) Stock Today: Alzheimer’s Registry Launch, Analyst Price Targets, and 2026 Catalysts (Dec. 18, 2025)
Thermo Fisher Scientific said Thursday it enrolled the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry, aimed at collecting real-world evidence on neurodegenerative care. Shares traded near $561 in the afternoon, down slightly after a 1.33% drop Wednesday. The registry will track long-term safety and effectiveness of Alzheimer’s treatments, including MRI-based monitoring of drug side effects.